

Brian G Weinshenker

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/386035/brian-g-weinshenker-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

207
papers

37,153
citations

69
h-index

192
g-index

230
ext. papers

43,916
ext. citations

8.3
avg, IF

7.04
L-index

#	Paper	IF	Citations
207	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 8, 20552173211052159	2	0
206	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103356	4	2
205	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
204	Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 250-258	5	13
203	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 303-308	5	25
202	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211048761	2	0
201	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211052656	2.56	1
200	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211048401	5	4
199	Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. <i>Nature Reviews Neurology</i> , 2021 , 17, 759-773	15	9
198	MOG-IgG1 and co-existence of neuronal autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1175-1186	5	6
197	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	6
196	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021 , 89, 895-910	9.4	23
195	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. <i>JAMA Neurology</i> , 2021 , 78, 351-364	17.2	11
194	Vessel Wall Enhancement in Unilateral Primary Angiitis of the Central Nervous System. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-3	1	
193	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021 , 78, 741-746	17.2	23
192	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 667-673	5	2
191	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 630-635	5	9

190	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 895-902	5	1
189	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1037-1045	5	1
188	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. <i>Neurology: Clinical Practice</i> , 2021 , 11, e601-e611	1.7	5
187	Spinal Cord Compression and Myelopathies 2021 , 251-278		
186	Biomechanical muscle stiffness measures of extensor digitorum explain potential mechanism of McArdle sign. <i>Clinical Biomechanics</i> , 2021 , 82, 105277	2.2	0
185	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2052-2061	5	4
184	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021 , 97, e1097-e1109	6.5	17
183	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021 , 97, e1351-e1358	6.5	9
182	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021 , 20, 762-772		37
181	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. <i>Mayo Clinic Proceedings</i> , 2021 ,	6.4	4
180	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. <i>JAMA Neurology</i> , 2020 , 77, 937-946	17.2	37
179	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102251	4	46
178	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7, e727	9.1	14
177	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
176	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020 , 95, e111-e120	6.5	65
175	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020 , 11, 501	4.1	93
174	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology, The</i> , 2020 , 19, 402-412	24.1	137
173	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	13

172	Reproductive history and progressive multiple sclerosis risk in women. <i>Brain Communications</i> , 2020 , 2, fcaa185	4.5	7
171	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101487	4	20
170	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?. <i>Neurology</i> , 2020 , 94, 85-88	6.5	15
169	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 85	51.1	77
168	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. <i>JAMA Neurology</i> , 2020 , 77, 1572-1575	17.2	6
167	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	40
166	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 1352-1363	40	247
165	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019 , 18, 185-197	24.1	74
164	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019 , 142, 1858-1875	11.2	150
163	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019 , 142, 1310-1323	11.2	75
162	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 488-490	5.5	33
161	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 35, 34-35	4	2
160	McArdle Sign: A Specific Sign of Multiple Sclerosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1427-1435	6.4	4
159	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019 , 93, e414-e420	6.5	14
158	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101413	4	10
157	Unilateral motor progression in MS: Association with a critical corticospinal tract lesion. <i>Neurology</i> , 2019 , 93, e628-e634	6.5	10
156	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019 , 76, 301-309	17.2	141
155	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. <i>JAMA Neurology</i> , 2019 , 76, 56-63	17.2	70

154	Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 709-714	5	1
153	Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. <i>Neurology</i> , 2018 , 90, 1106-1112	6.5	12
152	Cervical spinal cord atrophy: An early marker of progressive MS onset. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e435	9.1	43
151	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , 2018 , 17, 162-173	24.1	2419
150	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. <i>JAMA Neurology</i> , 2018 , 75, 892-895	17.2	13
149	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. <i>Ophthalmology</i> , 2018 , 125, 1628-1637	7.3	59
148	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 162-167	3.2	17
147	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 331-339	5	29
146	Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018 , 195, 8-15	4.9	171
145	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1445-1452	5	11
144	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018 , 75, 1355-1363	17.2	159
143	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibody-Positive Meningoencephalitis. <i>Journal of Neuro-Ophthalmology</i> , 2018 , 38, 276-281	2.6	18
142	Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. <i>Neurology</i> , 2018 , 91, e1642-e1651	6.5	84
141	Population-based study of "no evident disease activity" in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e495	9.1	4
140	Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. <i>Annals of Neurology</i> , 2017 , 81, 298-309	9.4	200
139	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 218-225	5.5	40
138	Elsberg syndrome: A rarely recognized cause of cauda equina syndrome and lower thoracic myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e355	9.1	37
137	Ball-concentric sclerosis evolving from apparent tumefactive demyelination. <i>Neurology</i> , 2017 , 88, 2150-2152	5.2	13

136	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e343	9.1	36
135	Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. <i>Neurology</i> , 2017 , 88, 2067-2068	6.5	
134	Neuromyelitis Spectrum Disorders. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 663-679	6.4	153
133	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e339	9.1	20
132	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2017 , 89, 2238-2244	7.4	38
131	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1808-1817	5	27
130	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - NO. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1190-1192	5	8
129	The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. <i>Neurology</i> , 2016 , 87, 1393-9	6.5	150
128	Disease modifying therapies for relapsing multiple sclerosis. <i>BMJ, The</i> , 2016 , 354, i3518	5.9	109
127	Central canal enhancement and the trident sign in spinal cord sarcoidosis. <i>Neurology</i> , 2016 , 87, 743-4	6.5	64
126	Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. <i>Neurology</i> , 2016 , 87, 1713-1719	6.5	47
125	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. <i>Scientific Reports</i> , 2016 , 6, 28484	4.9	437
124	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016 , 79, 437-47	9.7	102
123	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 862-72	5	51
122	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2016 , 86, 491-2	6.5	51
121	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016 , 263, 140-9	5.5	40
120	Atypical inflammatory demyelinating syndromes of the CNS. <i>Lancet Neurology, The</i> , 2016 , 15, 967-981	24.1	86
119	What Is the Optimal Sequence of Rescue Treatments for Attacks of Neuromyelitis Optica Spectrum Disorder?. <i>Annals of Neurology</i> , 2016 , 79, 204-5	9.4	7

118	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016 , 79, 775-783	9.4	173
117	Pediatric familial neuromyelitis optica in two sisters with long term follow-up. <i>Journal of Clinical Neuroscience</i> , 2016 , 29, 183-4	2.2	5
116	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. <i>Neurology</i> , 2015 , 85, 722-9	6.5	65
115	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2015 , 15, 57	6.6	22
114	Corticosteroid-Induced Paraplegia A Diagnostic Clue for Spinal Dural Arterial Venous Fistula. <i>JAMA Neurology</i> , 2015 , 72, 833-4	17.2	18
113	Teaching Neurolmages: Primary Sjögren syndrome presenting as isolated lesion of medulla oblongata. <i>Neurology</i> , 2015 , 85, 204-5	6.5	1
112	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015 , 85, 177-89	6.5	2255
111	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. <i>Neurology: Clinical Practice</i> , 2015 , 5, 175-177	1.7	14
110	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015 , 84, 1805-15	6.5	30
109	Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1746-7	5	9
108	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, e4.40-e4	5.5	54
107	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e134	9.1	79
106	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015 , 84, 148-58	6.5	39
105	Relapses and disability accumulation in progressive multiple sclerosis. <i>Neurology</i> , 2015 , 84, 81-8	6.5	75
104	Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. <i>JAMA Neurology</i> , 2015 , 72, 81-7	17.2	162
103	Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 693-4	5	2
102	Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4. <i>Neurology: Genetics</i> , 2015 , 1, e19	3.8	
101	Neuromyelitis Optica 2014 , 153-162		

100	Neuromyelitis optica spectrum disorders. <i>Current Neurology and Neuroscience Reports</i> , 2014 , 14, 483	6.6	35
99	Anterior spinal artery infarction causing man-in-the-barrel syndrome. <i>Neurology: Clinical Practice</i> , 2014 , 4, 268-269	1.7	7
98	The investigation of acute optic neuritis: a review and proposed protocol. <i>Nature Reviews Neurology</i> , 2014 , 10, 447-58	15	188
97	Neuromyelitis optica (Devic syndrome). <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 122, 581-99	3	38
96	Clinical spectrum of neuromyelitis optica 2013. <i>Neurology and Clinical Neuroscience</i> , 2014 , 2, 23-27	0.3	2
95	Specific pattern of gadolinium enhancement in spondylotic myelopathy. <i>Annals of Neurology</i> , 2014 , 76, 54-65	9.4	61
94	Pregnancy outcomes in a woman with neuromyelitis optica. <i>Neurology</i> , 2014 , 83, 1576-7	6.5	12
93	Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. <i>JAMA Neurology</i> , 2014 , 71, 48-54	17.2	44
92	Hydrocephalus in neuromyelitis optica. <i>Neurology</i> , 2014 , 82, 1841-3	6.5	18
91	Evaluation of aquaporin-4 antibody assays. <i>Clinical and Experimental Neuroimmunology</i> , 2014 , 5, 290-303	0.4	76
90	Teaching neuroimages: MRI in advanced neuromyelitis optica. <i>Neurology</i> , 2014 , 82, e101-2	6.5	4
89	Longitudinally extensive transverse myelitis. <i>Current Opinion in Neurology</i> , 2014 , 27, 279-89	7.1	45
88	Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1404-6	5	4
87	Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. <i>JAMA Neurology</i> , 2013 , 70, 1118-25	7.25	52
86	Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. <i>Current Neurology and Neuroscience Reports</i> , 2013 , 13, 403	6.6	61
85	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. <i>Lancet Neurology</i> , 2013 , 12, 554-62	24.1	278
84	Intractable nausea and vomiting from autoantibodies against a brain water channel. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 240-5	6.9	43
83	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. <i>Neurology: Clinical Practice</i> , 2013 , 3, 448-451	1.7	5

82	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology</i> , 2013 , 81, 1197-204	6.5	157
81	Christian Confavreux (1949 - 2013). <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1811-2	5	1
80	Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013 , 19, 944-67	3	12
79	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 188-98	5	148
78	Teaching neuroimages: "pancake-like" gadolinium enhancement suggests compressive myelopathy due to spondylosis. <i>Neurology</i> , 2013 , 80, e229	6.5	8
77	Acute demyelinating disorders: emergencies and management. <i>Neurologic Clinics</i> , 2012 , 30, 285-307, ix-x	4.5	8
76	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 5-10	5	157
75	Spinal Cord Compression and Myelopathies 2012 , 235-257		
74	Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of African or African-Caribbean heritage. <i>Journal of the Neurological Sciences</i> , 2012 , 312, 21-5	3.2	19
73	Treatment of Neuromyelitis Optica: Review and Recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 180-187	4	176
72	Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. <i>Neurology</i> , 2012 , 78, 540-46.5		32
71	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: no. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1211-2	5	1
70	Effects of age and sex on aquaporin-4 autoimmunity. <i>Archives of Neurology</i> , 2012 , 69, 1039-43		67
69	Plasmapheresis: are bigger studies necessarily better?. <i>Nature Reviews Neurology</i> , 2012 , 8, 410; author reply 410	15	1
68	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
67	Lupus related longitudinal myelitis. <i>Journal of Rheumatology</i> , 2011 , 38, 1520; author reply 1521	4.1	5
66	Beneficial plasma exchange response in central nervous system inflammatory demyelination. <i>Archives of Neurology</i> , 2011 , 68, 870-8		145
65	Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. <i>Archives of Neurology</i> , 2011 , 68, 953-5		28

64	Association of IL2RA polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 634-6	5	7
63	Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?. <i>Neurology</i> , 2011 , 76, 768-9	6.5	
62	Neuromyelitis Optica. <i>Blue Books of Neurology</i> , 2010 , 35, 258-275		3
61	Compressive myelopathy mimicking transverse myelitis. <i>Neurologist</i> , 2010 , 16, 120-2	1.6	24
60	HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 981-4	5	18
59	Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. <i>Brain</i> , 2010 , 133, 333-48	11.2	134
58	Japanese optic-spinal MS: is it MS or neuromyelitis optica and does the answer dictate treatment?. <i>Neurology</i> , 2010 , 75, 1404-5	6.5	4
57	Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. <i>Neurology</i> , 2010 , 74, 1478-9; author reply 1479	6.5	4
56	Approach to acute or subacute myelopathy. <i>Neurology</i> , 2010 , 75, S2-8	6.5	38
55	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2010 , 133, 2626-34	11.2	232
54	Intractable vomiting as the initial presentation of neuromyelitis optica. <i>Annals of Neurology</i> , 2010 , 68, 757-61	9.4	139
53	Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. <i>Archives of Neurology</i> , 2009 , 66, 1128-33		229
52	Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. <i>Archives of Neurology</i> , 2009 , 66, 1134-8		72
51	Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. <i>Archives of Neurology</i> , 2009 , 66, 964-6		21
50	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. <i>Muscle and Nerve</i> , 2009 , 39, 87-90	3.4	104
49	Gait apraxia in multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 2009 , 36, 562-5	1	7
48	Neuromyelitis optica and non organ-specific autoimmunity. <i>Archives of Neurology</i> , 2008 , 65, 78-83		387
47	Laquinimod, a new oral drug for multiple sclerosis. <i>Lancet, The</i> , 2008 , 371, 2059-60	40	5

46	Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. <i>Archives of Neurology</i> , 2008 , 65, 1443-8		376
45	Acute disseminated encephalomyelitis: current understanding and controversies. <i>Seminars in Neurology</i> , 2008 , 28, 84-94	3.2	111
44	Neuromyelitis Optica and Autoimmune DiseasesReply. <i>Archives of Neurology</i> , 2008 , 65, 992		3
43	An approach to the diagnosis of acute transverse myelitis. <i>Seminars in Neurology</i> , 2008 , 28, 105-20	3.2	169
42	Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. <i>Archives of Neurology</i> , 2008 , 65, 349-57		27
41	Neuromyelitis optica. <i>Current Treatment Options in Neurology</i> , 2008 , 10, 55-66	4.4	113
40	Neuromyelitis optica: changing concepts. <i>Journal of Neuroimmunology</i> , 2007 , 187, 126-38	3.5	90
39	The spectrum of neuromyelitis optica. <i>Lancet Neurology, The</i> , 2007 , 6, 805-15	24.1	1584
38	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. <i>Brain</i> , 2007 , 130, 1194-205	11.2	556
37	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. <i>Neurology</i> , 2007 , 68, 1326; author reply 1327	6.5	12
36	More on Multiple Sclerosis and Neuromyelitis OpticaReply. <i>Archives of Neurology</i> , 2007 , 64, 1802		4
35	Neuromyelitis optica is distinct from multiple sclerosis. <i>Archives of Neurology</i> , 2007 , 64, 899-901		69
34	Neuromyelitis optica. <i>Current Opinion in Neurology</i> , 2007 , 20, 255-60	7.1	76
33	OSMS is NMO, but not MS: proven clinically and pathologically. <i>Lancet Neurology, The</i> , 2006 , 5, 110-1	24.1	63
32	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. <i>Annals of Neurology</i> , 2006 , 59, 566-9	9.4	474
31	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. <i>Archives of Neurology</i> , 2006 , 63, 964-8		560
30	Brain abnormalities in neuromyelitis optica. <i>Archives of Neurology</i> , 2006 , 63, 390-6		563
29	NMO-IgG: a specific biomarker for neuromyelitis optica. <i>Disease Markers</i> , 2006 , 22, 197-206	3.2	70

28	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 1178-86	4	31
27	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. <i>Lancet, The</i> , 2005 , 366, 579-82	40	355
26	Natural history of multiple sclerosis. <i>Neurologic Clinics</i> , 2005 , 23, 17-38, v	4.5	93
25	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
24	Neuromyelitis Optica. <i>Current Treatment Options in Neurology</i> , 2005 , 7, 173-182	4.4	80
23	The natural history of recurrent optic neuritis. <i>Archives of Neurology</i> , 2004 , 61, 1401-5		91
22	Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. <i>Neurology</i> , 2004 , 63, 1788-95	6.5	356
21	Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. <i>Annals of Neurology</i> , 2004 , 56, 303-6	9.4	183
20	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. <i>Lancet, The</i> , 2004 , 364, 2106-12	40	2296
19	Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. <i>American Journal of Clinical Pathology</i> , 2003 , 120, 672-675	1.9	49
18	Neuromyelitis optica: what it is and what it might be. <i>Lancet, The</i> , 2003 , 361, 889-90	40	73
17	Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. <i>Clin Ther.</i> 2003;25:105-118. <i>Clinical Therapeutics</i> , 2003 , 25, 1888-90	3.5	1
16	Neuromyelitis optica: clinical predictors of a relapsing course and survival. <i>Neurology</i> , 2003 , 60, 848-53	6.5	264
15	A role for humoral mechanisms in the pathogenesis of Devic@ neuromyelitis optica. <i>Brain</i> , 2002 , 125, 1450-61	11.2	825
14	Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. <i>Journal of Clinical Apheresis</i> , 2001 , 16, 39-42	3.2	36
13	A point mutation in PTPRC is associated with the development of multiple sclerosis. <i>Nature Genetics</i> , 2000 , 26, 495-9	36.3	170
12	Multiple sclerosis. <i>New England Journal of Medicine</i> , 2000 , 343, 938-52	59.2	2821
11	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. <i>Annals of Neurology</i> , 1999 , 46, 878-86	9.4	682

10	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. <i>Journal of Clinical Apheresis</i> , 1999 , 14, 144-8	3.2	34
9	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system 1999 , 14, 144		1
8	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease 1999 , 46, 878		2
7	Familial chordoma with probable autosomal dominant inheritance. <i>American Journal of Medical Genetics Part A</i> , 1998 , 75, 335-6		36
6	The natural history of multiple sclerosis: update 1998. <i>Seminars in Neurology</i> , 1998 , 18, 301-7	3.2	67
5	ACUTE LEUKOENCEPHALOPATHIES. <i>Neurologist</i> , 1998 , 4, 148-166	1.6	16
4	Screening for major depression in the early stages of multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 228-31	1	66
3	Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. <i>Journal of Clinical Apheresis</i> , 1995 , 10, 163-70	3.2	30
2	Natural history of multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36 Suppl, S6-11	9.4	228
1	Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. <i>Neurology: Clinical Practice</i> , 10.1212/CPJ.0000000000001149	1.7	1